UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 21, 2011
SPECTRUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware |
|
001-35006 |
|
93-0979187 |
| (State or other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
| |
|
|
11500 S. Eastern Ave., Ste. 240, Henderson, NV
|
|
89052 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (702) 835-6300
| |
Not Applicable
|
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
|
|
|
| Item 7.01 |
|
Regulation FD Disclosure. |
On June 21, 2011, Spectrum Pharmaceuticals, Inc. (the “Company”) issued a press release,
which, among other matters, announced that the Company expects to report record second quarter and
full-year 2011 revenues. As with all forward looking statements, there can be no assurance that
such results will be achieved.
|
|
|
| Item 9.01 |
|
Financial Statements and Exhibits. |
| |
|
|
|
|
| Exhibit No. |
|
Description |
| |
|
|
|
|
| |
99.1 |
|
|
Press Release dated June 21, 2011 (filed herewith). |
Forward-looking statement This Form 8-K contains forward-looking statements regarding
future events and the future performance of Spectrum Pharmaceuticals that involve risks
and uncertainties that could cause actual results to differ materially. These statements
include but are not limited to statements that relate to our business and its future
financial results, Spectrum’s ability to identify, acquire, develop and commercialize
a broad and diverse pipeline of late-stage clinical and commercial products, leveraging
the expertise of partners and employees around the world to assist us in the execution
of our strategy, the safety and efficacy of ZEVALIN, FUSILEV, apaziquone, and belinostat,
and any statements that relate to the intent, belief, plans or expectations of Spectrum
or its management, or that are not a statement of historical fact. Risks that could
cause actual results to differ include the possibility that our existing and new drug
candidates, may not prove safe or effective, the possibility that our existing and
new drug candidates may not receive approval from the FDA, and other regulatory agencies
in a timely manner or at all, the possibility that our existing and new drug candidates,
if approved, may not be more effective, safer or more cost efficient than competing
drugs, the possibility that our efforts to acquire or in-license and develop additional
drug candidates may fail, our lack of revenues, our limited marketing experience, our
dependence on third parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further detail in the Company’s
reports filed with the Securities and Exchange Commission. We do not plan to update any
such forward-looking statements and expressly disclaim any duty to update the information
contained in this Form 8-K except as required by law.
The information in this Current Report on Form 8-K is furnished pursuant to Item 7.01
and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall
it be deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, except as shall be expressly set forth by specific
reference in such a filing.
2
